Skip to content
DataLookout
Menu

NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 3 years 2 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 27 versions: 27 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 1, 2027 to Nov 19, 2030 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 126 words
    • Enrollment increased: 740 → 890 participants
    • Trial sites expanded: 94 → 97 locations
    • Study completion pushed from Oct 10, 2028 to Aug 19, 2031
    • Secondary endpoints revised (16)
    • Study description revised
  2. Minor Study sites: 94 to 96
  3. Minor Trial sites expanded: 91 → 94 locations
  4. Minor Study sites: 90 to 91
  5. Notable Eligibility criteria expanded, about 51 words Show 4 more changesShow less
    • Secondary endpoints: details revised at 2 of 16 entries
    • Site details revised at 3 of 90 sites
    • Collaborators: details revised at 1 of 1 entry
    • Publications: details revised at 1 of 1 entry
  6. Minor Study sites: 89 to 90v22
  7. Minor Trial sites expanded: 86 → 89 locationsv21
  8. Minor Study sites: 85 to 86v20
  9. Minor Site details revised at 3 of 85 sitesv19
  10. Minor Study sites: 84 to 85v18
  11. Minor Study sites: 80 to 84v17
  12. Minor Study sites: 78 to 80v16
  13. Minor Study sites: 77 to 78v15
  14. Minor Study sites: 75 to 77v14
  15. Notable Enrollment target: 400 to 740v13 Show 6 more changesShow less
    • Primary completion date: Jun 30, 2025 to Sep 1, 2027
    • Eligibility criteria expanded, about 305 words
    • Study sites: 63 to 75
    • Study completion date: Apr 30, 2026 to Oct 10, 2028
    • Secondary endpoints: 15 to 16
    • Study description expanded, about 3 words
  16. Minor Study sites: 62 to 63v12
  17. Minor Study sites: 61 to 62v11
  18. Minor Study sites: 60 to 61v10
  19. Minor Study sites: 57 to 60v9
  20. Minor Study sites: 56 to 57v8
  21. Minor Study sites: 54 to 56v7
  22. Minor Study sites: 52 to 54v6
  23. Minor Study sites: 10 to 52v5
  24. Notable Eligibility criteria shortened, about 2 words
    • Study sites: 3 to 10
    v4
  25. Notable Enrollment target: 120 to 400v3 Show 4 more changesShow less
    • Eligibility criteria expanded, about 634 words
    • Primary endpoints: 1 to 2
    • Study sites: 1 to 3
    • Secondary endpoints: 11 to 15
  26. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 28, 2024 to Feb 26, 2024
    v2
  27. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Timeframe: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
Proportion of Participants Achieving a ≥50% Decrease in Prostate-specific Antigen (PSA) (Prostate Cancer Cohort Only)
Timeframe: Baseline, each cycle before infusion (each cycle is 21 days), and end of treatment, up to approximately 27 months

Secondary (16)

Overall Number of Participants With Treatment-emergent Adverse Events Following HER3-DXd Monotherapy (All Cohorts)
Duration of Response as Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Clinical Benefit Rate as Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Disease Control Rate as Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Time to Response as Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Show 11 moreShow less
Progression-free Survival as Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Overall Survival Following HER3-DXd Monotherapy (All Cohorts)
Pharmacokinetic Parameter Maximum Serum Concentration for HER3-DXd (All Cohorts)
Pharmacokinetic Parameter Time to Maximum Serum Concentration for HER3-DXd (All Cohorts)
Pharmacokinetic Parameter Trough Serum Concentration (Ctrough) for HER3-DXd (All Cohorts)
Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd (All Cohorts)
Radiographic Progression-free Survival (rPFS) as Assessed by Prostate Cancer Working Group 3 (PCWG3) Criteria by the Investigator or Death Due to Any Cause Following HER3-DXd Monotherapy (Prostate Cancer Cohort Only)
Proportion of Participants Achieving a ≥30% Decrease in PSA (Prostate Cancer Cohort Only)
Time to First Subsequent Anticancer Therapy (TFST) (Prostate Cancer Cohort Only)
Time to First Symptomatic Skeletal-Related Event (SSRE) (Prostate Cancer Cohort Only)
Correlation Between HER3 Protein Expression and Efficacy

Arms and interventions

HER3-DXd MonotherapyExperimental

Participants with locally advanced unresectable or metastatic cancer (melanoma, head and neck, gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, breast cancer, and cervical 2L/3L cancer) will receive an intravenous infusion of HER3-DXd monotherapy 5.6 milligrams per kilogram (mg/kg) every 3 weeks (Q3W).

Drugs: HER3-DXd

Sites

97 sites in 16 countries

United States 14, Japan 13, France 9, Spain 9, South Korea 8, Taiwan 8, United Kingdom 6, Australia 5, Belgium 5, Netherlands 5, Canada 4, Italy 4, Norway 3, China 2, Germany 1, Hungary 1